It is not as active a drug as Jakafi and is a JAK2 and FLT3 inhibitor. It is an effective drug but has greater side effects than Jakafi, especially gastrointestinal AEs, probably because of FLT3 inhibition. I don't think it's as good a drug as Jakafi.
And that, incidentally, is the thing to watch for the next 2 CCs: safety. Jakafi is shaping up as an extraordinarily safe drug so far. If no safety problems turn up in the next 4 months they aren't likely to. And a first-in-class with no safety problems is very hard to knock off its perch.